LEO Foundation Center for Cutaneous Drug Delivery - Scientific Advisory Board
Scientific Advisory Board
The Scientific Advisory Board is composed of members covering different scientific and development perspectives, identified from the Center vision of being cross-disciplinary, yet focusing on the physico-chemical aspects of cutaneous drug delivery.
The role of the Scientific Advisory Board is to provide strategic advice to Center and Department management, and to illuminate strategic ideas and decisions by a group of scientifically excellent researchers from pharmaceutical as well as natural and medical scientific perspectives.
Members of the Scientific Advisory Board
Prof. Richard Guy, Department of Pharmacy and Pharmacology, University of Bath, UK. Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco, the University of Geneva and, since 2004, the University of Bath as Professor of Pharmaceutical Sciences. In 2013, Dr. Guy received the Controlled Release Society's Founders Award and, in 2016, he was awarded the degree of Doctor of Science from Oxford University. Dr. Guy's research focuses on skin barrier function characterization and the prediction, assessment and optimization of topical drug bioavailability. He has published 350+ peer-reviewed articles and over 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. Within the Scientific Advisory Board, Prof. Guy will provide expertise in dermal drug delivery.
|Prof. Frank Caruso, Chemical and Biomolecular Engineering, University of Melbourne, Australia. Professor Caruso is ARC Australian Laureate Fellow at The University of Melbourne, Australia, and also Deputy Director, ARC Centre of Excellence on Convergent Bio-Nano Science and Technology. He is also leader of the Nanostructured Interfaces and Materials Science (NIMS) Group. He received his PhD degree in 1994 from the University of Melbourne, and then moved to the CSIRO Division of Chemicals and Polymers in Melbourne. He was an Alexander von Humboldt Research Fellow and then group leader at the Max Planck Institute of Colloids and Interfaces (Berlin, Germany) from 1997 until 2002.
His research interests focus on developing advanced nano- and biomaterials for biotechnology and medicine. He has published over 300 peer-reviewed papers and is on the ISI most highly cited list, ranking in the top 20 worldwide, in materials science in 2011. Within the Scientific Advisory Board, Prof. Caruso will provide expertise in nanotechnology.
|Prof. Lise Arleth, Neutron and X-Ray Science Group, Niels Bohr Institute, University of Copenhagen, Denmark. Professor Arleth works within biophysics and physical chemistry with the main focus on structural investigations of macromolecules and their aggregates in solution. The research involves self-organizing systems such as microemulsions, surfactants and polymers in solution, as well as more complex biological and/or pharmaceutically relevant systems, such as proteins/enzymes and their interactions with lipids and surfactants. Her main experimental technique is small-angle scattering (X-rays and neutrons), in which she is an acclaimed international expert. Professor Arleth has been, and still is, instrumental for the engagement of the University of Copenhagen in MAX-Lab IV and ESS in Lund. She is the author over more than 75 peer-reviewed papers, and is also associated with the Center of Synthetic Biology. Within the Scientific Advisory Board, Prof. Arleth will provide expertise in X-ray and neutron-based analytical tools for investigation of soft matter.
|Prof. Artur Schmidtchen, senior consultant within Dermatology at Lund University hospital, is Professor and Assistant Head at the Department of Clinical Sciences, Lund University, Sweden, where he leads a research group that focuses on translational research within innate immunity, wound healing, and skin infection and inflammation. As Professor and Scientific Director Dermatology at LKCMedicine, Nanyang Technological University, Singapore, he was involved in building up translational research within dermatology during 2014-2016. Activities as consultant for companies, external advisor for investment funds, as well as co-founder and founder of several companies has provided experience in R&D and therapeutic development. Schmidtchen has authored and co-authored over 120 papers, including high impact journals as Nature Communications, PNAS, Blood, J Clinical Investigation, J Immunology, J Biol Chem, and PLoS Pathogens. He is a member of the board of the Welander-Finsen Foundation, and co-editor for Acta Dermato-Venereologica. Within the Scientific Advisory Board, Prof. Schmidtchen will provide medical/clinical expertise, and also cover strategic Øresund aspects.
|Dr. Karsten Petersson, LEO Pharma A/S, Denmark. Karsten Petersson received his PhD within Pharmaceutical Chemistry from the University of Copenhagen in 2004. During 2004-2006, he worked at LEO Pharma and Novo Nordisk, focusing on the early pharmaceutical drug development and on bringing pharmaceutical aspects into the drug discovery projects. Since 2006, he has held several senior scientific and management positions within Global R&D at LEO Pharma, mainly focusing on new product opportunities and life cycle management. Here, he has lead the pharmaceutical design and early development of dermal drug products by combining an extensive knowledge of skin diseases and patient needs with that of dermal drug delivery and pharmaceutical technologies. Within the scientific advisory board, Dr. Petersson will provide expertise in industry-academia collaborative efforts, as well as a general industrial perspective.